Clinical Trials Directory

Trials / Completed

CompletedNCT02926664

Delta qSOFA for Risk Stratification in Emergency Infected Patients

Prognostic Value of Quick Sequential Organ Failure Assessment Kinetics After Fluids Challenge in the Emergency Department

Status
Completed
Phase
Study type
Observational
Enrollment
512 (actual)
Sponsor
Societe Française de Medecine d'urgence · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study will investigate the prognostic value of qSOFA (quick Sequential Organ Failure Assessment) kinetics between H0 and H1, and between H0 and H3 in patients with suspicion of Sepsis, i.e. an initial qSOFA of at least of 2.

Detailed description

qSOFA has been reported as a good tool for risk stratification in the ED for patients with infection. However, it is not clear whether qSOFA remains stable during the ED stay, nor whether its kinetics can have prognostic added value. Patients with a qSOFA of at least 2 in the ED, and suspicion of infection will be included. After treatment is initiated and fluids challenge performed, we will collect qSOFA value at 1 hour and 3 hours. Our hypothesis is that a decrease in qSOFA between H0 and H3 is associated with better outcome. We assume that 50% of patients will have a deltaqSOFA \>0, with an overall mortality of 23% (according to previous cohort). Under the hypothesis of difference of at least 15% in mortality between the two groups (DeltaqSOFA \> 0 and Delta qSOFA\<=0), with a power of 90% and an alpha of 0.05, we need to recruit 322 patients.

Conditions

Interventions

TypeNameDescription
OTHERmeasurement of qSOFAqSOFA will be measured at H0, H1 and H3

Timeline

Start date
2016-10-01
Primary completion
2017-05-01
Completion
2017-05-01
First posted
2016-10-06
Last updated
2017-10-24

Locations

10 sites across 3 countries: Belgium, France, Spain

Source: ClinicalTrials.gov record NCT02926664. Inclusion in this directory is not an endorsement.

Delta qSOFA for Risk Stratification in Emergency Infected Patients (NCT02926664) · Clinical Trials Directory